Biochemical and histologic determinants in the prognosis of neuroblastoma

Stanley E. Gitlow, Laura Bertani Dziedzic, Lotte Strauss, Steven M. Greenwood, Stanley W. Dziedzic

Research output: Contribution to journalArticlepeer-review

76 Scopus citations

Abstract

Of 98 consecutive patients with neuroblastoma, 54 could be separated into survivor and non‐survivor groups on the basis of an opportunity for a 2 year minimum period of observation. Their excretions of the catecholamine metabolites, vanillylmandelic acid (VMA), homovanillic acid (HVA), 3‐methoxy‐4‐hydroxyphenylethyleneglycol (MHPG), and total metanephrines (TM) were assayed at the moment of their initial diagnosis as well as following therapy. Histologic specimens were evaluated independently by two pathologists at different institutions. Age‐at‐diagnosis, sex, catecholamine catabolite excretion pattern before and following therapy, histology, and prognosis were subjected to a statistical study of association probability. A better prognosis was associated with an age‐at‐onset of less than two years, greater histologic differentiation, lower initial HVA excretion, and a rapid return of catecholamine metabolism to normal following therapy. These data suggest the availability of criteria by which a prognostically useful classification of neuroblastoma may be established.

Original languageEnglish
Pages (from-to)898-905
Number of pages8
JournalCancer
Volume32
Issue number4
DOIs
StatePublished - Oct 1973
Externally publishedYes

Fingerprint

Dive into the research topics of 'Biochemical and histologic determinants in the prognosis of neuroblastoma'. Together they form a unique fingerprint.

Cite this